T1 Evidence in Adults

toujeo logo

Toujeo® can support your patients with T1DM.

Discover the Toujeo® Evidence in T1DM below and get access to patient supporting tools and materials for your T1 patients who have been prescribed Toujeo®.


Toujeo vs Insulin Glargine 100 U/mL Toujeo vs Insulin Degludec 100 U/mL

Toujeo vs Insulin Glargine 100 U/mL

Toujeo is associated with a more stable & prolonged activity profile than insulin glargine 100 U/mL

Toujeo® is associated with less within-day fluctuation vs insulin degludec 100 U/mL.

The within day variability of the smoothed GIR curve was similar between Toujeo 0.6 units/kg/day and insulin degludec 0.6 units/kg/day. Both insulins provided exposure and activity until 30 hours (end of clamp).

The clinical implications of PK/PD data require further evaluation including CGM and larger clinical studies. The results of euglycaemic clamp studies do not necessarily predict clinical outcomes in all patients.


Toujeo vs Insulin Glargine 100 U/mL

Meta Analysis

Toujeo vs Insulin Glargine 100 U/mL
Post-hoc meta-analysis of three EDITION 6-month, Phase III, randomised clinical trials5

Post-hoc meta-analysis aim: Exploring the risk for severe hypoglycaemia with Toujeo® vs insulin glargine 100 units/mL in the pool of studied patients with T1DM.

Edition 4 (549 adults), Edition Junior (463 children), Edition JP 1 (245 adults).

Meta Analysis 

Real World Evidence: Sparta

Toujeo vs other basal insulins

A multicentre, UK, retrospective, observational study to assess the effectiveness of Toujeo® in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA).
Primary endpoint: Change in HbA1c levels from baseline to Month 6 after Toujeo® initiation.

298 patients with T1DM were recruited.

Sparta Summary  ``    Sparta Video

ONGOING STUDY: Toujeo® vs Insulin Degludec 100 U/mL

The first H2H RCT comparing Toujeo® vs insulin degludec 100 U/mL in T1DM4

Objective: To demonstrate non-inferiority of Toujeo® vs insulin degludec 100 U/mL in the percentage of time in range (TIR) [3.9-10 mmol/L] in adults with T1DM.

Study Design: Multicentre, randomised, active-controlled, parallel-group, 12-week, open label, phase 4 study will collect CGM data over 20 consecutive days from adults with T1D randomised to recieve Gla-300 or IDeg-100.


Toujeo® Coach

Toujeo® Coach is a patient support programme, developed and funded by Sanofi. It is delivered by registered healthcare professionals from Ashfield Healthcare and is available for adult diabetes patients who have been prescribed Toujeo®.

With Toujeo® Coach, patients will receive one-to-one telephone coaching support from a Specialist Nurse, Dietician and/or Psychologist. Find out more below.

HCP Information Leaflet HCP Referral Form

Patient Information Leaflet Patient Registration Form

 Toujeo T1 Starter Packs

 Download an easy to use patient starter kit which you can share digitally with   your adult patients with T1DM who have recently started with Toujeo.

Toujeo starter PACKS

This site uses cookies to store information on your computer. Some cookies on this site are needed because the site won’t work as expected without them. To learn more about cookies, please read our Cookie Policy.
By closing this message or using the website, you agree to our use of cookies on this device in agreement with our Cookie Policy, unless you have turned them off.
Accept and close